Mini-monoka punctocanaliculoplasty manages canalicular stenosis

Article

Epiphora secondary to punctal and canalicular stenosis is successfully managed by mini-monoka punctocanaliculoplasty.

Epiphora secondary to punctal and canalicular stenosis is successfully managed by mini-monoka punctocanaliculoplasty, according to a study in the British Journal of Ophthalmology.

Dr R.N. Hussain et al., Department of Ophthalmology, Leicester Royal Infirmary, Infirmary Square, Leicester, UK, performed a retrospective case note analysis on 123 eyes of 77 consecutive patients.

Of the eyes studied, 73% had punctal stenosis, 72% had canalicuar stenosis, 46% had both punctal stenosis and canalicuar stenosis, 20% had some severity of lid laxity and 29% had nasolacrimal duct stenosis.

After treatment, 82% of the eyes demonstrated a significant improvement in symptoms. The success rate was raised to 88% when structural comorbidity patients were excluded from the study.

It was discovered that mini-monoka punctocanaliculoplasty is an effective, safe, simple and fairly non-invasive treatment for epiphora secondary to punctal and/or canalicular stenosis.

Recent Videos
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
© 2025 MJH Life Sciences

All rights reserved.